Ken Griffin Shattuck Labs, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.0 - $4.85 $8,400 - $13,579	-2,800 Reduced 90.32%	300 $1,000
Q2 2024 Aug 14, 2024	SELL	$3.56 - $11.18 $45,568 - $143,104	-12,800 Reduced 80.5%	3,100 $11,000
Q1 2024 May 15, 2024	SELL	$7.37 - $10.09 $28,743 - $39,351	-3,900 Reduced 19.7%	15,900 $142,000
Q4 2023 Feb 14, 2024	BUY	$1.37 - $7.24 $26,167 - $138,284	19,100 Added 2728.57%	19,800 $141,000
Q3 2023 Nov 14, 2023	BUY	$1.42 - $3.16 $994 - $2,212	700 New	700 $1,000
Q1 2023 May 15, 2023	BUY	$2.5 - $4.72 $11,000 - $20,768	4,400 Added 2200.0%	4,600 $13,000
Q4 2022 Feb 14, 2023	BUY	$1.96 - $3.26 $392 - $652	200 New	200 $0

28.8M

300

1.2K

Ticker STTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,382,000
Market Cap $46.6M
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.